Time to presentation and mortality outcomes among patients with diabetes and acute myocardial infarction

Abstract

Background/Aims: Due to limited real-world evidence on the association between time to presentation (T2P) and outcomes following acute myocardial infarction and diabetes (AMI-DM), we investigated the characteristics of patients with AMI-DM and their outcomes based on their T2P.Methods: 4,455 patients with AMI-DM from a Korean nationwide observational cohort (2011–2015) were divided into early and late presenters according to symptom-to-door time. The effects of T2P on three-year all-cause mortality were estimated using inverse probability of treatment weighting (IPTW) and survival analysis.Results: The incidence of all-cause mortality was consistently higher in late presenters than in early presenters (11.4 vs. 17.2%; <i>p</i> < 0.001). In the IPTW-adjusted dataset, the incidence of all-cause mortality was numerically higher in late presenters than in early presenters (9.1 vs. 12.4%; <i>p</i> = 0.072). In the survival analysis, the cumulative incidence of all-cause mortality was significantly higher in late presenters than in early presenters before and after IPTW. In the subgroup with ST-elevation myocardial infarction, late presenters had a higher incidence of cardiac death than early presenters before (4.8 vs. 10.5%; <i>p</i> < 0.001) and after IPTW (4.2 vs. 9.7%; <i>p</i> = 0.034). In the initial glycated hemoglobin (HbA1c)-stratified analysis, these effects were attenuated in patients with HbA1c ≥ 9.0% before (adjusted hazard ratio [HR]: 1.45, 95% confidence interval [CI]: 0.80-2.64) and after IPTW (adjusted HR: 0.82, 95% CI: 0.40-1.67).Conclusions: Late presentation was associated with higher mortality in patients with AMI-DM; therefore, multifaceted and systematic interventions are needed to decrease pre-hospital delays.

Acute Myocardial Infarction During VRD Chemotherapy in a Patient With Multiple Myeloma: A Clinical Case

“…Слід зазначити, що цукровий діабет 2 типу (ЦД2) один з основних факторів ризику атеросклеротичних кардіоваскулярних ускладнень. Особливої уваги заслуговує розвиток атипових симптомів захворювань ССС на тлі ЦД2, в тому числі, й під час розвитку гострого ІМ, що в пода-льшому може призводити до несвоєчасного надання медичної допомоги пацієнтам з відповідною коморбітною патологією [8].…”